Approval · Notice of Compliance 20817 · 2018
RESTORIL: Notice of Compliance 20817
Issued May 2, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20817
- Date
- May 2, 2018
- Company
- AA Pharma Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To change the manufacturing, packaging, labelling and quality control site. The changes to the site also require a change to the formulation, manufacturing process, drug product imprinting and primary container closure system
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RESTORIL | Not yet assigned | — |